The RIGL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RIGL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The RIGL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View RIGL Detailed Price Forecast - CNN Money | View RIGL Detailed Summary - Google Finance | ||
View RIGL Detailed Summary - Yahoo! Finance | View RIGL Stock Research & Analysis - Zacks.com |
View RIGL Trends & Analysis - Trade-Ideas | View RIGL Major Holders - Barrons | ||
View RIGL Call Transcripts - NASDAQ | View RIGL Breaking News & Analysis - Seeking Alpha | ||
View RIGL Annual Report - CompanySpotlight.com | View RIGL OTC Short Report - OTCShortReport.com | ||
View RIGL Fundamentals - TradeKing | View RIGL SEC Filings - Bar Chart | ||
View Historical Prices for RIGL - The WSJ | View Performance/Total Return for RIGL - Morningstar | ||
View the Analyst Estimates for RIGL - MarketWatch | View the Earnings History for RIGL - CNBC | ||
View the RIGL Earnings - StockMarketWatch | View RIGL Buy or Sell Recommendations - MacroAxis | ||
View the RIGL Bullish Patterns - American Bulls | View RIGL Short Pain Metrics - ShortPainBot.com |
View RIGL Stock Mentions - StockTwits | View RIGL Stock Mentions - PennyStockTweets | ||
View RIGL Stock Mentions - Twitter | View RIGL Investment Forum News - Investor Hub | ||
View RIGL Stock Mentions - Yahoo! Message Board | View RIGL Stock Mentions - Seeking Alpha |
View Insider Transactions for RIGL - SECform4.com | View Insider Transactions for RIGL - Insider Cow | ||
View RIGL Major Holdings Summary - CNBC | View Insider Disclosure for RIGL - OTC Markets | ||
View Insider Transactions for RIGL - Yahoo! Finance | View Institutional Holdings for RIGL - NASDAQ |
View RIGL Stock Insight & Charts - FinViz.com | View RIGL Investment Charts - StockCharts.com | ||
View RIGL Stock Overview & Charts - BarChart | View RIGL User Generated Charts - Trading View |
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Posted on Friday April 12, 2024
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Posted on Wednesday April 10, 2024
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 407,325 stock options to nine non-executive employees on April 4, 2024, and 187,500 stock options to Lisa Rojkjaer, Rigel's Chief
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Posted on Thursday April 04, 2024
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Posted on Tuesday March 12, 2024
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background.